<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/9669938#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by KIT in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT signaling is important in several processes including stem cell maintenance, erythropoiesis, mast cell development, lymphopoiesis, melanogenesis and maintenance of interstitial cell of Cajal (Hirota et al, 1998; Chi et al, 2010). Gain-of-function mutations in KIT have been identified at low frequency in a number of diseases, including AML, melanoma and mast and germ cell tumors, and at higher frequency in gastrointesinal stromal tumors (reviewed in Lennartsson and Roonstrand, 2012; Abbaspour Babaei et al, 2016; Roskoski, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by kinase domain mutants of KIT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating mutations in the kinase domain of KIT are found in a small number of cases of AML and melanoma, as well as in myeloproliferative syndromes, mastocytosis and germ cell tumors (Longley et al, 1996; 1999; Nagata et al, 1995; Beghini et al, 2000; Ning et al, 2001; Tian et al, 1999; Kemmer et al, 2004; reviewed in Roskoski, 2018; Meng and Carvajal, 2019). Mutations in the kinase domain and activation loop of KIT (encoded by exons 13, 14 and 17) also arise in gastrointestinal stromal tumors (GIST) as primary mutations ( 1%) and as secondary resistance mutations in response to treatment with imatinib (Chen et al, 2004; Serrano et al, 2019; Gajiwala et al, 2008; McLean et al, 2008; reviewed in Antonescu, 2006; Roskoski, 2018; Wu et al, 2019; Corless et al, 2011). Activating kinase mutants of KIT are constitutively active in the absence of ligand and can be tyrosine phosphorylated in the absence of dimerization (Furitsu et al, 1993; Hirota et al, 1998; Tsujimura et al, 1994).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by juxtamembrane domain KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the juxtamembrane region of KIT, encoded by exon 11, are especially prevalent as initiating events in gastrointestinal stromal tumors (GIST), but are also found at lower frequency in other cancers such as AML and melanoma (reviewed in Antonescu, 2006; Roskoski, 2018). Mutations in this region of KIT are believed to disrupt an auto-inhibitory function, leading to constitutive enzyme activation (Ma et al, 1999; Chan et al, 2003; Mol et al, 2004; reviewed in Roskoski, 2018). Unlike kinase domain mutants, juxtamembrane domain KIT mutants still undergo dimerization, although in a ligand-independent manner (Hirota et al, 1998; Furitsu et al, 1993; reviewed in Lennartsson and Roonstrand, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by extracellular domain mutants of KIT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Many of the described KIT mutations are located in the fifth Ig-like domain, encoded by exon 8 and 9. The fifth Ig-like domain of KIT plays a critical role in stabilizing the receptor dimers formed upon SCF binding, allowing these mutations to support constitutive activation of the receptor (Yuzawa et al, 2007; reviewed in Lennartsson and Ronnstrand, 2012)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the PI3K/mTOR, RAS/MAPK and STAT signaling pathways has been observed downstream of activated extracellular, juxtamembrane and kinase domain mutants of KIT, although downstream signaling has not been studied in great detail in all cases. Activation of these pathways contributes to cellular proliferation, avoidance of apoptosis, and actin cytoskeletal organization (Dunesing et al, 2004; Bauer et al, 2007; Chi et al, 2010; Bosbach et al, 2017; reviewed in Lennartsson and Roonstrand, 2012; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating mutations in the juxtamembrane domain of KIT are common in some cancers, including gastrointestinal stromal tumors, melanoma and acute myeloid leukemia (reviewed in Roskoski, 2018). These mutations are sensitive to inhibition with imatinib, which in 2001 was the first tyrosine kinase inhibitor approved for treatment of cancer (Demetri et al, 2002; Corless et al, 2011; reviewed in Zitvogel, 2016). Although highly successful in prolonging survival, imatinib-resistance develops in most patients due to appearance of secondary mutations, often in the ATP-binding pocket or in the activation loop of the kinase domain (Gajiwala et al, 2008; Serrano et al, 2019; reviewed in Roskoski, 2018; Napolitano and Vincenzi, 2019)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib is approved for treatment of cancers carrying primary mutations in the KIT receptor. Imatinib binds and inhibits the inactive state of the receptor, including the conformation promoted by exon 11 mutations that relieve the auto-inhibition of the WT protein. Resistance to imatinib arises due to the polyclonal expansion of subpopulations bearing secondary KIT mutations in the ATP binding pocket or the activation loop of the protein (Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib is a class II tyrosine kinase inhibitor that is often used as a second line treatment in KIT-mutated cancers that develop resistance to imatinib (Heinrich et al, 2008; Serrano et al, 2017; reviewed in Roskoski, 2018; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib is a type II tyrosine kinase inhibitor that is approved for treatment of advanced gastrointestinal stromal tumors with KIT mutations. Regorafenib is effective in imatinib-resistant tumors carrying secondary mutations in exon 14 (gatekeeper mutation), and most KIT secondary mutations encoded by exons 17 and 18 (the activation loop) (Demetri et al, 2013; Serrano et al, 2017, Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; ).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
 <bp:stepProcess rdf:resource="#Catalysis3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Catalysis1" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
 <bp:stepProcess rdf:resource="#Catalysis2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind SFKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JAK2 binds to p-KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind GRB2-SOS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of STATs downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of KIT extracellular domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of extracellular domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of KIT juxtamembrane domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of juxtamembrane domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive phosphorylation of kinase domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants:PI3K catalyze synthesis of PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of STATs downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of STATs by KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-KIT mutants:GRB2:SOS catalyzes nucleotide exchange on RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant KIT mutants do not bind regorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib-resistant KIT mutants do not bind sunitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant KIT mutants do not bind imatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of JAK2 downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disassociation and translocation of STATs to the nucleus downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated KIT mutants bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#Catalysis7" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
 <bp:stepProcess rdf:resource="#Catalysis4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
 <bp:stepProcess rdf:resource="#Catalysis6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction12" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind ripretinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction15" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction16" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind type II TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant KIT mutants do not bind sorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction1" />
</bp:Catalysis>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction2" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction4" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction6" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib is a type II tyrosine kinase inhibitor that is active against KIT receptors with mutations in the juxtamembrane and activation loop domains, but shows only partial activity against KIT receptors with mutations at residue V654 (Schittenhelm et al, 2006; Serrano et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Masitinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mastinib is a class II tyrosine kinase inhibitor that targets mutant and wild-type FGFR3, PDGFR and c-KIT (Dubreuil, 2009). Masitinib, like imatinib, is effective in inhibiting the activity of juxtamembrane mutant forms of KIT, but is ineffective against many of the mutations in the activation loop and ATP-binding cleft of the receptor (Dubreuil, 2009; Serrano et al, 2019; reviewed in Demetri, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib is a type II tyrosine kinase inhibitor currently in clinical trials for treatment of KIT-mutant cancers, and shows variable effectiveness against mutations in exon 11, 13, 17 and 18. Nilotinib is ineffective against the gatekeeper mutation T670I (Kissova et al, 2016; Guo et al, 2007; Roberts et al, 2007; Serrano et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib-resistant KIT mutants do not bind nilotinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Masitinib-resistant KIT mutants do not bind masitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib-resistant KIT mutants do not bind dasatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib is a type II tyrosine kinase inhibitor that is approved for use in hepatocellular and renal cell carcinoma. It is active against KIT receptors with mutations in the ATP-binding cleft and the activation loop, with the exception of substitutions at D816, which are resistant (Guida et al, 2007; Heinrich et al, 2012; Serrano et al, 2019; Weisberg et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of KIT can be inhibited by tyrosine kinase inhibitors. Primary mutations in KIT are frequently found in exon 11, encoding the juxtamembrane domain responsible for autoinhibition of the kinase. These mutations are generally sensitive to tyrosine kinase inhibitors such as imatinib. Accumulation of secondary mutations in the ATP-binding pocket and the activation loop of the kinase domain contributes to resistance to first line tyrosine kinase inhibitors. KIT receptors with in these regions are sensitive to a panel of additional tyrosine kinase inhibitors such as sunitinib and regorafenib (Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; Serrano et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>
</rdf:RDF>